Opdivo (Nivolumab) drug approved for the treatment of urothelial carcinoma!

The FDA has expanded the use of Opdivo by US pharmaceutical company Bristol-Myers Squibb, Reuters reported. The drug has been approved for the treatment of urothelial carcinoma.

Opdivo has already been approved for the treatment of melanoma, non-small cell lung cancer, kidney cancer, and Hodgkin's lymphoma.

B Last month, Bristol-Myers Squibb announced that it would not seek FDA approval for the fast review of the Opdivo (nivolumab) and Yervoy (ipilimumab) combination as first-line therapy for lung cancer.